6-n-Propyl-8-methoxy-methyl or methylmercaptomethylergolines and related compounds as prolactin inhibitors and to treat Parkinson&#39;s syndrome

ABSTRACT

6-n-Propyl (ethyl or allyl)-8β-methoxy-(methyl-sulfinyl, methylsulfonyl, or methylmercapto) methylergolines, 8-ergolenes or 9-ergolenes, useful as prolactin inhibitors and in the treatment of Parkinsonisn.

This is a division, of application Ser. No. 875,978 filed Feb. 8, 1978pending

BACKGROUND OF THE INVENTION

Compounds based on the ergoline ring system: ##STR1## have a suprisingvariety of pharmaceutical activities. For example, many of the amides oflysergic acid, which is 8β-carboxy-6-methyl-9-ergolene, have valuableand unique pharmacologic properties. (The trivial name "ergoline" isgiven to the above structure and the 9,10 double bonded compound-relatedto lysergic acid is called a 9-ergolene rather than a9,10-didehydroergoline. The name D-ergoline or D-8-ergolene orD-9-ergolene is used herein in naming specific compounds. The letter "D"indicates that the C-5 carbon atom configuration has the absolutestereochemistry designated as R and that the hydrogen is β--above theplane of the ring system. However, modern usage has tended to omit the"D", on the ground that the newly synthesized ergolines or ergolenes areuniversally derivatives of natural products such as lysergic acid orelymoclavine, all of which have R stereochemical--"D"series--configuration and in which the stereochemical integrity at C-5is maintained. It should be understood that all of the compounds orclasses of ergolines or ergolenes disclosed herein also have the Rstereochemical configuration, whether or not the specific or genericname is preceded by a "D".) Among these pharmacologically active amidesof lysergic acid are included naturally occurring oxytoxicalkaloids--ergocornine, ergokryptine, ergonovine, ergocristine,ergosine, ergotamine, etc.--and synthetic oxytocics such as methergineas well as the synthetic hallucinogen-lysergic acid diethylamide or LSD.The amides of 6-methyl-8-carboxyergoline, known generically asdihydroergot alkaloids, are oxytocic agents of lower potency and alsolower toxicity than the ergot alkaloids themselves. Recently, it hasbeen found by Clemens, Semonsky, Meites, and their various co-workersthat many ergot-related drugs have activity as prolactin inhibitors.Ergocornine, dihydroergocornine, 2-bromo-α-ergokryptine andD-6-methyl-8-cyanomethylergoline are examples of such drugs. Referencesembodying some of the newer findings in the field of ergoline chemistryinclude the following: Nagasawa and Meites, Proc. Soc. Exp't'l. Biol.Med., 135, 469 (1970); Lutterbeck et al., Brit. Med. J., 228, (July 24,1971); Heuson et al., Europ. J. Cancer, 353 (1970); Coll. Czech. Chem.Commun., 33, 577 (1968); Nature, 221, 666 (1969); Seda et al., J.Reprod. Fert., 24, 263 (1971); Mantle and Finn, id, 441; Semonsky andco-workers, Coll. Czech. Chem. Comm., 36, 2200 (1971); Schaar andClemens, Endocr., 90, 285-8 (1972); Clemens and Schaar, Proc. Soc. Exp.Biol. Med., 139, 659-662 (1972), Bach and Kornfeld, Tetrahedron Letters,3225 (1974) and Sweeney, Clemens, Kornfeld and Poore, 64th AnnualMeeting, American Association for Cancer Research, April 1973. Recentlyissued patents in the field of ergolines or of lysergic acid derivativesinclude the following: U.S. Pat. No. 3,923,812, U.S. Pat. No. 3,929,796,U.S. Pat. No. 3,944,582, U.S. Pat. No. 3,934,772, U.S. Pat. No.3,954,988, U.S. Pat. No. 3,957,785, U.S. Pat. No. 3,959,288, U.S. Pat.No. 3,966,739, U.S. Pat. No. 3,968,111, U.S. Pat. No. 4,001,242. Manyother related and older patents can be found in Patent OfficeClassification Files 260-256.4 and 260-285.5.

Parkinson's disease, also known as paralysis agitans or shaking palsy,was first described in the late 18th century. It is characterized bytremor, muscular rigidity and loss of postural reflexes. The diseaseusually progresses slowly with intervals of 10 to 20 years elapsingbefore the symptoms cause incapacity. The terms "Parkinsonism" and "theParkinsonian syndrome" include not only Parkinson's disease but alsodrug-induced Parkinsonism and post-encephalitic Parkinsonism. Treatmentof Parkinsonism involves symtomatic, supportive and palliative therapy.Parkinson's disease has been treated with various anticholinergicagents, which agents have a greater beneficial effect on rigidity andakinesia than on tremor. More recently 1-dopa (1-dihydroxyphenylalanine)has been used because of the (finding that there is an alteredcatecholamine content in the brains of patients afflicted withParkinsonism. Unfortunately, 1-dopa is rapidly metabolized. It has beensuggested, therefore, that monoamineoxidase inhibitors be used to retardthe degradation of cerebral catechol amines. The use of 1-dopa with adecarboxylase inhibitor was also designed to increase the level of1-dopa in the brain and hopefully thereby to alleviate the symptoms ofParkinsonism. It has also been suggested (by Corrodi and coworkers) thatcertain ergot derivatives, such as the naturally occurring alkaloid,ergocornine, are direct dopamine receptor stimulants of long durationand may therefore prove to be of value in the treatment of Parkinson'sdisease [see J. Pharm. Pharmac., 25, 409 (1973)]. Johnson et al. inExperientia, 29, 763 (1973) discuss the evidence of Corrodi et al. thatergocornine and 2-bromo-α-ergokryptine stimulate dopamine receptors andextended their observations to other ergot alkaloids. Trever W. Stonewriting in Brain Research, 72, 1977 (1974) verified the aboveexperiments and produced further evidence that ergot alkaloids have adopamine receptor stimulating action.

RELEVANT PRIOR ART

A majority of the chemical modification work carried out in the field ofthe ergot alkaloids has involved the preparation of synthetic amides oflysergic acid having some, but not all, of the properties of one or moreof the naturally-occurring alkaloids. Even with the more recent researchdevoted to finding prolactin inhibitors without CNS effects, chemicalinterest has centered on derivatizing the 8-position of the ergolinering system. However, there are several publications describing thereplacement of the 6-methyl group in an ergoline with other groups,particularly higher alkyl groups. Fehr, Stadler and Hoffman, Helv. Chim.Acta, 53, 2197 (1970) reacted lysergic acid and dihydrolysergic acidmethylesters with cyanogen bromide. Treatment of the resulting 6-cyanoderivative with zinc dust and acetic acid yielded the corresponding6-norderivative, alkylation of which with ethyl iodide, for example,produced a mixture of 6-nor-6-ethyllysergic acid methyl ester and thecorresponding isolysergic acid ester. 6-Ethyl-8β-methoxycarbonylergoline(the 6-ethyl-9,10 dihydro derivative of methyl lysergate) was alsoprepared. No utility was given for either of these new derivatives.Bernardi, et al. Il Farmaco-Ed. Sci., 30, 789 (1975) prepared severalanalogues of the alpha blocker, nicergoline, Starting materials includedsuch compounds as 1-methyl-6-ethyl (ally,cyclopropylmethyl)-8β-hydroxymethyl-10α-methoxyergoline. These startingmaterials were in turn converted to the corresponding10α-methoxy-8β-(5-bromonicotinylmethyl) derivatives. In a recent paper,Krepelka, Army, Kotva and Semonsky, Coll. Czech. Chem. Commun., 42, 1209(1977) prepared 6-alkyl analogues of 8β-cyanomethylergoline and of8β-methylergoline (6-norfestuclavine) including the 6-ethyl, 6-n-propyl,6-isopropyl, 6-n-butyl, 6-isobutyl and 6-n-heptyl derivatives. Thesecompounds increased "antilactation and antinidation" effects in rats by"an order of magnitude" as compared with the corresponding 6-methylderivatives. Details of such biological testing was to be forthcoming,according to the authors. Cassady and Floss, Lloydia, 40, 90 (1977)reported the preparation of 6-alkyl derivatives of elymoclavine(6-methyl-8-hydroxymethyl-8-ergolene). According to their publishedfigures, prolactin inhibitory effects increased on increasing the sizeof the alkyl group at N-6 from methyl to propyl but fell off with abutyl substituent. Niwaguchi, et al., J. Pharm. Soc. (Japan) (YakugakaZasshi) 96, 673 (1976) prepared 6-norlysergic acid diethylamide andrealkylated this intermediate to prepare the corresponding 6-allyl,6-ethyl and 6-n-propyl derivatives of LSD. Their pharmacology isdiscussed in Hashimoto et al., Europ. J. Pharm., 45, 341 (1977).

U.S. Pat. No. 3,920,664 discloses D-2-halo-6-alkyl (methyl, ethyl,n-propyl)-8β-cyanomethylergolines prepared by demethylating thecorresponding 6-methyl compound and realkylating as taught by theprocedure of Fehr et al. (supra). U.S. Pat. No. 3,901,894 discloses6-methyl-8β-methylmercaptomethylergolines optionally substituted at C-2by chlorine or bromine. U.S. Pat. No. 3,959,288 discloses the analogous8-methoxymethyl compounds.

Most of the above ergolines or ergolenes are active prolactininhibitors. Some of these compounds have also proved to be useful in thetreatment of Parkinsonism; i.e. α-bromoergokryptine(bromocriptine)-Brit. J. Clin. Pharm., 3, 571 (1976), Brit. Med. J., 4,(1974) page 442 and legotrile-Neurology, 25, 459 (1975).

DESCRIPTION OF THE INVENTION

This invention provides a group of extremely potent prolactin inhibitorsand drugs for treating Parkinsonism belonging to the ergoline series andhaving the following structure: ##STR2## wherein Y is O, SO, SO₂ or S,R¹ is ethyl, n-propyl, or allyl, X is H, Cl or Br and R², R³ and R⁴ whentaken singly are hydrogen, and R² and R³, and R³ and R⁴, when takentogether with the carbon atoms to which they are attached, form a doublebond, and pharmaceutically-acceptable acid addition salts thereof.

The pharmaceutically-acceptable acid addition salts of this inventioninclude salts derived from inorganic acids such as: hydrochloric acid,nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodicacid, nitrous acid, phosphorous acid and the like, as well as saltsderived from nontoxic organic acids such as aliphatic mono anddicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoicand alkandioic acids, aromatic acids, aliphatic and aromatic sulfonicacids, etc. Such pharmaceutically-acceptable salts thus include sulfate,pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate,monohydrogenphosphate, dihydrogenphosphate, metaphosphate,pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate,decanoate, caprylate, acrylate, formate, isobutyrate, caprate,heptanoate, propiolate, oxalate, malonate, succinate, suberate,sebacate, fumarate, maleate, mandelate, butyne-1,4-dioate,hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate,dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate,terephthalate, benzenesulfonate, toluenesulfonate,chlorobenzenesulfonate, xylenesulfonate, phenylacetate,phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate,glycollate, malate, tartrate, methanesulfonate, propanesulfonate,naphthalene-1-sulfonate, naphthalene-2-sulfonate and the like salts.

Illustrative compounds coming within the scope of this inventioninclude:

D-6-ethyl-8β-methylmercaptomethylergoline maleate

D-2-chloro-6-n-propyl-8β-methoxymethylergoline succinate

D-6-allyl-8β-methylmercaptomethylergoline hydrochloride

D-2-bromo-6-allyl-8β-methoxymethylergoline tartrate

D-6-n-propyl-8β-methylmercaptomethyl-9-ergolene hydrobromide

D-6-n-propyl-8-methoxymethyl-8-ergolene maleate

D-2-chloro-6-allyl-8β-methoxymethyl-9-ergolene benzoate

D-2-bromo-6-ethyl-8-methylmercaptomethyl-8-ergolene phosphate

D-6-ethyl-8β-methylsulfinylmethylergoline

D-6-n-propyl-8β-methylsulfonylmethyl-9-ergolene maleate

D-6-n-propyl-8-methylsulfinylmethyl-8-ergolene tartrate

D-2-chloro-6-allyl-8β-methylsulfinylergoline succinate

D-2-bromo-6-allyl-8β-methylsulfinyl-9-ergolene

A preferred group of compounds are those according to Formula II inwhich R¹ is n-propyl, Y is S and R², R³, R⁴ and X have the same meaningas before. A particularly preferred group are those in which R¹ isn-propyl, Y is S, X is H and R², R³, and R⁴ have the meaning previouslyassigned. Another preferred group of compounds are those withsulfur-containing groups at C-8; i.e., those in which Y is S, SO or SO₂and in which R¹ is n-propyl and R², R³ and R⁴ are each hydrogen.

The compounds of this invention can be prepared by various routes from anumber of different starting materials. One readily available startingmaterial is lysergic acid (D-6-methyl-8β-carboxy-9-ergolene) produced byfermentation of selected Claviceps species. Esterification of thecarboxyl at C-8 followed by reduction of the thus-formed ester groupyields an 8-hydroxymethyl group. This same compound can be produced fromelymoclavine, another starting material available from fermentation bythe process of U.S. Pat. No. 3,709,891.

The 6-methyl group of D-6-methyl-8β-hydroxymethyl-9-ergolene producedfrom either starting material can be removed and replaced by an ethyl,an allyl, or an n-propyl group according to the procedure of U.S. Pat.No. 3,920,664, Example 8. According to this procedure, cyanogen bromidealone, or preferably in an inert solvent, is reacted with, for example,D-6-methyl-8β-hydroxymethyl-9-ergolene to yield the corresponding6-cyano derivative. Suitable inert solvents for this reaction includechlorinated hydrocarbons such as chloroform, methylenedichloride, carbontetrachloride, and ethylenedichloride, aromatic hydrocarbons includingbenzene, toluene or xylene; and polar solvents such as DMA, DMF, andDMSO. The reaction temperature is not critical and temperatures fromambient temperature to the boiling point of the solvent used may beemployed. The cyanide group is readily removed as by reduction with zincdust in acetic acid, thus producing a secondary amine function at N-6,which amine can be alkylated with, for example, ethyl iodide in thepresence of base, to yield D-6-ethyl-8β-hydroxymethyl-9-ergolene. Thezinc-acetic acid cleavage reaction is usually carried out near theboiling point of the solvent: 100°-120° C. Cleavage of the cyano groupcan also be accomplished by acidic or basic hydrolysis. In addition,other reducing agents can be employed in place of zinc and acetic acidsuch as Raney nickel and hydrogen. Alternatively, the N-methyl group canbe removed from a 9-ergolene by reaction with a chloroformate such asmethyl chloroformate, phenyl chloroformate, benzyl chloroformate,trichloroethyl chloroformate and the like to form an intermediarycarbamate which can be cleaved to yield the desired 6-nor secondaryamine. Alkylation of the secondary amine with an ethyl, n-propyl orallyl halide, tosylate, etc. is carried out in an inert solvent,preferably a polar solvent such as DMA, DMF, acetonitrile, nitromethaneand the like at temperatures in the range 20°-50° C. Suitable baseswhich may be present in the reaction mixture as acid scavengers includeinsoluble inorganic bases such as sodium carbonate, potassium carbonate,sodium bicarbonate, sodium hydroxide, and the like, as well as solublebases such as the tertiary amines, particularly the aromatic tertiaryamines like pyridine. Next, the hydroxymethyl at C-8 is esterified witha readily replaceable group such as the p-toluenesulfonyloxy group orthe methanesulfonyloxy group (p-tosyl or mesyl derivatives). Theesterification reaction utilizes an acid halide or anhydride; i.e.,mesylchloride, p-tosyl bromide and the like. The reaction is carried outpreferably in an aromatic tertiary amine solvent such as collidine,pyridine, picoline, etc. The reaction temperature is in the range20°-50° C. This ester group can, in turn, be replaced with amethylmercapto group according to the procedure of U.S. Pat. No.3,901,894, Example 3. Similarly, the mesyloxy or p-tosyloxy group can bereplaced with a methoxy group by reaction with methanol in base or witha methylsulfonyl group by reaction with sodium methanesulfinate. Thisreplacement reaction can be carried out by forming a sodium salt; i.e.,sodium methylmercaptide, using a base such as NaH, KH, sodium methoxideor sodium ethoxide. A mutual inert polar solvent is employed such asDMA, DMF, or DMSO. The reaction mixture is usually heated to atemperature in the range 50°-100° C. Replacement of the mesyloxy orp-tosyloxy group by a methoxy group is usually carried out with methanolin the presence of a quaternary ammonium base.

9-Ergolenes having an 8-methylsulfinylmethyl group are prepared from thecorresponding 8-methylmercaptomethyl compound by reaction with periodateor like oxidizing agent at ambient temperature. Customarily, awater-soluble salt of the 9-ergolene is used and water is the reactionsolvent.

These 6-n-propyl (ethyl or allyl) 8-methoxy, methylsulfinyl,methylsulfonyl or methylmercaptomethyl-9-ergolenes thus prepared arecompounds coming within the scope of this invention. These compounds canin turn be chlorinated or brominated at C-2 by the procedure of U.S.Pat. No. 3,920,664 to yield those compounds of this invention in whichR¹ is Cl or Br and in which there is a Δ⁹ double bond. Halogenatingagents which can be employed in this procedure includeN-chlorosuccinimide, N-chloroacetanilide, N-chlorophthalimide,N-chlorotetrachlorophthalimide, 1-chlorobenzotriazole,N-chloro-2,6-dichloro-4-nitroacetanilide,N-chloro-2,4,6-trichloroacetanilide and sulfuryl chloride, this latterreagent being used either alone or with boron trifluoride etherate. Auseful solvent for the halogenation reaction with N-bromosuccinimide isdioxane. With N-chlorosuccinimide and most of the other positive halogencompounds, DMF is used but with SO₂ Cl₂, solvents such as CH₂ Cl₂, CH₃NO₂, CH₃ CN and the like are employed. The reaction is ordinarilycarried out at room temperature.

Lysergic acid, one of the starting materials used above, can also bereduced to the corresponding dihydro compound, dihydrolysergic acid, byprocedures available in the art as by catalytic hydrogenation using aplatinum oxide or other suitable catalyst in an inert mutual solvent,preferably a lower alkanol. Esterification by standard procedures yieldsmethyl dihydrolysergate for example. The methyl group at N-6 can then beremoved by reaction with cyanogen bromide as outlined above to yield asecondary amine group. The secondary amine can then be alkylated witheither ethyl iodide, n-propyl iodide or allyl bromide to yield acompound carrying an ethyl, n-propyl or allyl group at N-6 and amethoxycarbonyl (ester) group at C-8. The secondary amine canalternatively be acylated with acetyl chloride or propionyl chloride toyield the corresponding amide in the presence of a tertiary amine baseat ambient temperature. Reduction of the amide group at N-6 and of theester group at C-8 simultaneously by a metal hydride reducing agent suchas lithium aluminum hydride in THF at room temperature yields thecorresponding D-6-ethyl (or n-propyl)-8β-hydroxymethylergoline.Similarly, the D- 6-ethyl (or n-propyl, or allyl)-8β-methoxycarbonylcompound can be reduced to the corresponding 8β-hydroxymethyl derivativeby a metal hydride reducing agent such as LiAIH₄ or NaBH(OCH₃)₃ in anetheral solvent (diethylether or THF) at room temperature or such asNaBH₄ in ethanol at reflux temperature. Esterification of the hydroxy ofthe 8β-hydroxymethyl group with methanesulfonyl chloride as above toyield the mesyloxy derivative followed by the reaction of thisderivative with a salt of methanol, methanethiol, or methanesulfinicacid yields the compounds of this invention in which R², R³, R⁴ and Xare all H, R¹ and Y having the same meaning as hereinabove except when Yis SO, which compounds are prepared by oxidation of the sulfide (Y isS). Each of these derivatives can then be chlorinated or brominated atC-2 by the procedure of U.S. Pat. No. 3,920,664 to yield those compoundsaccording to the above formula in which X is Cl or Br, R², R³, and R⁴are hydrogen and R¹ and Y have the same meaning as before. The samereaction conditions are employed as were used for the preparation of thecorresponding Δ⁹ -ergolenes.

The above ergoline compounds can also be prepared from elymoclavine, theother readily available starting material, by reduction of the Δ⁸ doublebond to yield D-6-methyl-8β-hydroxymethylergoline. The same sequence ofreactions--replacement of the methyl at N-6 with an ethyl, n-propyl orallyl group followed by replacement of the hydroxymethyl with amethoxymethyl, methylsulfonylmethyl or methylmercaptomethyl group viathe intermediate mesylate ester--can be carried out as before.

Finally, elymoclavine itself can be subjected to the procedures setforth above in the reaction sequence based on methyl lysergate includingremoving the methyl group at N-6, involving reaction with cyanogenbromide and removal of the 6-cyano group, followed by reaction of thethus formed secondary amine with an alkyl of allyl halide to yield aD-6-ethyl, n-propyl or allyl-8-hydroxymethyl-8-ergolene. In thisinstance, since the hydroxyl of the hydroxymethyl group is an allylichydroxyl, replacement with chlorine is an available procedure and theallylic chlorine itself is readily replaced by a methoxy,methylsulfonyl, or methylmercapto group to yield those compounds of thisinvention in which R² is hydrogen, R³ and R⁴ form a double bond and Yand R¹ have the same meanings as before except where Y is SO, whichcompound is again prepared by oxidation of the corresponding sulfide.Although we prefer to use a mixture of triphenylphosphine and CCl₄ asthe chlorinating agent for allylic hydroxyl, other chlorinating agentscan be used such as HCl, HBr, diethylether hydrochloride, a phosphoroustrihalide or POCl₃, care being taken with these more powerful agents touse reaction conditions which avoid undesirable by-products. As before,any of the compounds of this invention in which X is Cl or Br can beprepared from the corresponding compound in which X is H as set forthabove. This chlorination or bromination at C-2 can take place with otherof the above intermediates in which there is, for example, an estergroup at C-8 and the ester group itself is later replaced by amethoxymethyl or methylmercaptomethyl group.

The compounds of this invention and their acid addition salts are whitecrystalline solids readily recrystallizable from organic solvents. Theirpreparation is illustrated by the following specific examples.

EXAMPLE 1

Preparation of D-6-n-Propyl-8β-methylmercaptomethylergoline.

A solution was prepared from 100 g. of methyl dihydrolysergate and 2.5l. of methylene dichloride. 100 g. of cyanogen bromide were added andthe reaction mixture stoppered and stored at room temperature for about24-25 hours. Thin-layer chromatography (TLC) of an aliquot of thesolution showed 1 major spot with some minor spots. The organic layer,containing methyl 6-cyano-8β-methoxycarbonylergoline formed in the abovereaction, was washed successively with aqueous tartaric acid, water andsaturated aqueous sodium chloride and was then dried. Evaporation of thesolvent in vacuo yielded a residue which, on TLC, showed one major spotless polar than starting material, said spot corresponding toD-6-cyano-8β-methoxycarbonylergoline. The compound thus prepared meltedat about 202°-5° C.; weight=98.5 g.

A reaction mixture containing 59.6 g. ofD-6-cyano-8β-methoxycarbonylergoline, 300 g. of zinc dust, 2.5 l. ofacetic acid and 500 ml. of water was heated under reflux in a nitrogenatmosphere for about 7 hours, and was then allowed to remain at ambienttemperature for another 16 hours. The reaction mixture was filtered andthe filtrate poured over ice. The resulting aqueous mixture was madebasic with 14 N aqueous ammonium hydroxide and the alkaline layerextracted with chloroform. The chloroform layer was separated, washedwith saturated aqueous sodium chloride, and then dried. Evaporation ofthe chloroform yielded a residue comprising D-8β-methoxycarbonylergolineformed in the above reaction; m.p.=154°-6° C.; weight=46.9 g. TLC showedone major spot and a smaller spot corresponding to starting material.

Alternatively, a solution of 98.5 g. ofD-6-cyano-8β-methoxycarbonylergoline was hydrogenated with Raney nickelin DMF (dimethylformamide) solution. The initial hydrogen pressure was50 psi. After completion, the hydrogenation mixture was filtered and thefiltrate concentrated in vacuo to a 200 ml. volume. This mixture waspoured into aqueous tartaric acid and the acidic layer extracted withethyl acetate. The acidic aqueous layer was then made basic with 14 Naqueous ammonium hydroxide and the alkaline layer extracted with ethylacetate. This ethyl acetate layer was separated, washed with water, withsaturated aqueous sodium chloride solution and then dried. Evaporationof the solvent in vacuo yielded D-8β-methoxycarbonylergoline melting at150°-3° C.; yield=68.8 g. (76 percent).

A reaction mixture was prepared from 10.8 g. ofD-8β-methoxycarbonylergoline, 10 ml. of n-propyl iodide and 8.2 g. ofpotassium carbonate in 200 ml. of DMF. The reaction mixture was stirredat room temperature under nitrogen for about 16 hours. TLC indicated onemajor spot with two minor spots. The reaction mixture was diluted withwater and the aqueous layer extracted with ethyl acetate. The ethylacetate extract was separated, washed with water, with saturated aqueoussodium chloride and then dried. Evaporation of the solvent in vacuoyielded a residue which gave essentially the same TLC pattern as before.The residue was dissolved in chloroform containing 2 percent methanoland filtered through 200 g. of florisil. Evaporation of the solvent invacuo yielded 8.55 g. of D-6-n-propyl-8β-methoxycarbonylergoline meltingat 203°-6° C.

About 720 mg. of D-6-n-propyl-8β-methoxycarbonylergoline were dissolvedin 25 ml. of dioxane and 50 ml. of methanol. 1 Gram of sodiumborohydride was added and the reaction mixture refluxed under nitrogenfor about 2 hours. A second gram of sodium borohydride was added afterone hour. TLC showed one major polar spot and a minor spot. The reactionmixture was cooled, diluted with water, and the aqueous mixtureextracted with a chloroform-isopropanol solvent mixture. The organiclayer was separated, washed with saturated aqueous sodium chloride anddried. Evaporation of the organic solvent yielded a residue consistingof D-6-n-propyl-8β-hydroxymethylergoline which was crystallized from anether-hexane solvent to yield crystals melting at about 167°-9° C.;yield=620 mg.

A solution was prepared from 31.2 g. ofD-6-n-propyl-8β-hydroxymethylergoline and 400 ml. of pyridine. Twentyml. of methanesulfonyl chloride was added slowly to the pyridinesolution. After the addition had been completed, the mixture was stirredfor about one hour and was then poured into an ice 14 N ammoniumhydroxide mixture. The alkaline aqueous layer was extracted with ethylacetate. The ethyl acetate layer was separated, was washed with waterand with saturated aqueous sodium chloride and was then dried.Evaporation of the organic solvent yielded a residue which, on TLC,consisted of one major spot with several minor spots. The chloroformsolution of the residue was chromatographed over 300 g. of florisilusing chloroform containing increasing amounts of methanol (from 0 to 4percent) as the eluant. D-6-n-propyl-8β-mesyloxymethylergoline obtainedin purified form from this chromatographic procedure melted at about178°-180° C. with decomposition; weight=25.6 g.

Analysis Calc: C, 62.96; H, 7.23; N, 7.77; S, 8.85. Found: C, 62.66; H,6.94; N, 7.46; S, 9.04.

Twenty-five grams of methylmercaptan were dissolved in 200 ml. ofdimethyl acetamide (DMA). The solution was cooled in an ice-water bathto about 0° C. Next, 14.4 g. of sodium hydride (as a 50 percentsuspension in mineral oil) were added in portions, thus forming thesodium salt of methylmercaptan. The sodium salt suspension was warmed toroom temperature. A solution of 10.9 g. ofD-6-n-propyl-8β-mesyloxymethylergoline in 60 ml. of DMA were slowlyadded. The reaction mixture was stirred for one hour under nitrogen andthen diluted with water. The aqueous layer was extracted with ethylacetate and the ethyl acetate layer separated. The separated layer waswashed with water and with saturated aqueous sodium chloride and wasthen dried. Evaporation of the solvent yielded a residue consisting ofD-6-n-propyl-8β-methylmercaptomethylergoline formed in the abovereaction. The residue showed a single major spot under TLC; weight=6.9g.; m.p.=206°-9° C. with decomposition. The residue was further purifiedby suspending it in 100 ml. of boiling methanol. 1.6 ml. ofmethanesulfonic acid in 10 ml. of methanol were added to the refluxingsolution. After the addition had been completed, the mixture was allowedto cool during which time crystals ofD-6-n-propyl-8β-methylmercaptomethylergoline methanesulfonateprecipitated. The solution was cooled and then filtered. 6.0 Grams ofsalt were obtained melting at about 255° C. with decomposition.

Analysis Calc: C, 58.50; H, 7.36; N, 6.82; S, 15.62. Found: C, 58.45; H,7.39; N, 6.92; S, 15.62.

EXAMPLE 2 Preparation of D-6-n-Propyl-8β-methoxymethylorgoline

A reaction mixture was prepared from 8.4 g. ofD-6-n-propyl-8β-mesyloxymethylergoline from Example 1, 50 ml. of a 40percent methanol solution of trimethylbenzylammoniummethylate and 200ml. of DMA as a solvent. The reaction mixture was refluxed under anitrogen atmosphere for about 1.25 hours. TLC showed 1 major spot inaddition to a starting material spot. The reaction mixture was cooledand diluted with ethyl acetate. The ethyl acetate layer was separated,washed with water and with saturated aqueous sodium chloride and thendried. The solvent was removed by evaporation. 5.00 g. of a residuecontaining D-6-n-propyl-8β-methoxymethylergoline were obtained. Thecompound melted at 233°-6° C. with decomposition. The methanesulfonatesalt was prepared as in Example 1 to yieldD-6-n-propyl-8β-methoxymethylergoline methanesulfonate melting at202°-4° C. after crystallization from ether-ethanol solvent mixture.Yield=4.09 g.

Analysis Calc: C, 60.89; H, 7.66; N, 7.10; S, 8.13. Found: C, 60.60; H,7.79; N, 7.18; S, 8.08.

EXAMPLE 3 Preparation of D-6-n-Propyl-8β-hydroxymethylergoline

A solution was prepared from 9.25 g. of D-8β-methoxycarbonylergoline and100 ml. of pyridine. 25 ml. of propionic anhydride were added and thereaction mixture stirred at room temperature for one hour. The reactionmixture was then poured into five percent aqueous ammonium hydroxide and2 liters of water were added. The subsequent mixture was cooled andfiltered. The filter cake containedD-6-propionyl-8β-methoxycarbonylergoline which melted at 260°-3° C. withdecomposition; weight=9.30 g.

Analysis Calc: C, 69.92; H, 6.79; N, 8.58. Found: C, 70.14; H, 6.99; N,8.73.

A suspension of 9.8 g. of D-6-propionyl-8β-methoxycarbonylergoline wasprepared in 1000 ml. of THF (tetrahydrofuran). Five grams of lithiumaluminum hydride were added in portions while the reaction mixture wascooled in an ice-water bath. After the addition of the lithium aluminumhydride had been completed, the reaction mixture was allowed to warm toambient temperature. It was then refluxed under a nitrogen atmospherefor about 16 hours. The reaction mixture was then cooled to about 0° C.and any excess lithium aluminum hydride plus other organometallicsdecomposed by the seriatim addition of ethyl acetate, ethanol and water.The reaction mixture was then diluted with water and the aqueous layerextracted several times with a chloroform-isopropanol solvent mixture.The organic extracts were separated, combined, and the combined extractswashed with saturated aqueous sodium chloride. The organic layer wasthen dried and the solvent removed by evaporation. The residue,comprising D-6-n-propyl-8β-hydroxymethylergoline formed in the abovereduction, was recrystallized from methanol to yield 4.75 g. of materialmelting at 174°-6° C. A second recrystallization from methanol yieldedD-6-n-propyl-8β-hydroxymethylergoline melting at 176°-8° C.

Analysis Calc: C, 76.02; H, 8.51; N, 9.85. Found: C, 75.73; H, 8.33; N,9.63.

This compound can be transformed via the mesylate ester to thecorresponding 8β-methylmercaptomethyl derivative etc.

EXAMPLE 4 Preparation of D-6-Allyl-8β-methylmercaptomethylergoline

Two grams of D-8β-methoxycarbonylergoline were dissolved in 75 ml. ofDMF. 1.7 g. of potassium carbonate were added followed by 0.71 ml. ofallyl bromide. The reaction mixture was stirred at ambient temperatureunder a nitrogen atmosphere for about 31/2 hours. TLC indicated a singlemajor fast-moving spot. The reaction mixture was diluted with water andthe resulting aqueous layer extracted with ethyl acetate. The ethylacetate layer was separated, washed with water, and with saturatedaqueous sodium chloride and then dried. Evaporation of the solvent invacuo yielded a residue which after recrystallization from methanol,yielded 570 mg. of D-6-allyl-8β-methoxycarbonylergoline melting at146°-8° C.

Analysis Calc: C, 73.52; H, 7.14; N, 9.03. Found: C, 73.27; H, 7.24; N,8.97.

Four and eight-tenths grams of D-6-allyl-8β-methoxycarbonylergoline weredissolved in a mixture of 50 ml. of dioxane and 100 ml. of methanol.Five grams of sodium borohydride were added and the resulting reactionmixture was heated to refluxing temperature for about 2 hours. A second2 g. batch of sodium borohydride was added after 1 hour. The reactionmixture was diluted with water and 14 N aqueous ammonium hydroxide. Thealkaline aqueous layer was extracted several times with achloroform-isopropanol solvent mixture. The organic extracts werecombined and the combined extracts washed with saturated aqueous sodiumchloride and then dried. Evaporation of the solvent yielded a residuecomprising D-6-allyl-8β-hydroxymethylergoline. The compound melted at204°-6° C. after recrystallization from a methanol-ether solventmixture.

Analysis Calc: C, 76.56; H, 7.85; N, 9.92. Found: C, 76.35; H, 7.72; N,9.65.

A solution was prepared from 3.77 g. ofD-6-allyl-8β-hydroxymethylergoline and 100 ml. of pyridine. 2.5 ml. ofmethanesulfonyl chloride were added and the resulting mixture stirred atambient temperature for about three hours. The reaction mixture was thendiluted with water and 14 N aqueous ammonium hydroxide. The aqueouslayer was extracted several times with ethyl acetate. The ethyl acetateextracts were combined, the combined extracts washed with water andsaturated aqueous sodium chloride and then dried. Evaporation of thesolvent yielded D-6-allyl-8β-mesyloxymethylergoline which melted at195°-6° C. with decomposition, after recrystallization from achloroformmethanol solvent mixture; yield=3.5 g.

Analysis Calc: C, 63.31; H, 5.71; N, 7.77; S, 8.89. Found: C, 63.03; H,6.49; N, 7.51; S, 8.68.

Following the procedure of Example 1, a sodium salt was prepared from 12g. of methylmercaptan, an excess of NaH and 150 ml. of DMF. A solutionof 4.3 g. of D-6-allyl-8β-mesyloxymethylergoline in 50 ml. of DMF wasadded rapidly to the sodium methylmercaptide mixture. The reactionmixture was stirred for one hour under a nitrogen atmosphere and wasthen diluted with water. The aqueous layer was extracted with ethylacetate. The ethyl acetate layer was separated, washed with water andwith saturated aqueous sodium chloride and then dried. Evaporation ofthe ethyl acetate yielded a residue comprisingD-6-allyl-8β-methylmercaptomethylergoline formed in the above reduction.The residue was dissolved in chloroform, and the chloroform solutionchromatographed over 200 g. of florisil using chloroform containingincreasing amounts of methanol (0-2 percent) as the eluant. 3.0 Grams ofD-6-allyl-8β-methylmercaptomethylergoline melting at 171°-3° C. wereobtained. The methanesulfonate salt was prepared as in Example 1, andmelted at 272°-4° C. with decomposition; yield=3.05 g.

Analysis Calc: C, 58.79; H, 6.91; N, 6.86; S, 15.70. Found: C, 58.63; H,6.76; N, 6.61; S, 15.71.

EXAMPLE 5 Alternate Preparation ofD-6-n-Propyl-8β-methoxycarbonylergoline

1.7 Grams of D-6-allyl-8β-methoxycarbonylergoline prepared by the methodof the previous example were dissolved in 40 ml. of THF and hydrogenatedover 0.5 g. of 5 percent palladium-on-carbon at embient temperature withan initial hydrogen pressure of 60 psi. After 23 hours, thehydrogenation was completed and the mixture filtered. The solvent wasevaporated from the filtrate in vacuo. The resulting residue gave twospots on TLC, one a new spot and the other corresponding to the 6-norcompound. The residue was dissolved in chloroform and the chloroformsolution chromatographed over 30 g. of florisil using chloroformcontaining increasing amounts of methanol (0 to 4 percent) as theeluant. Fractions containing D-6-n-propyl-8β-methoxycarbonylergoline asdetermined by TLC were combined and yielded crystalline material meltingat 204°-6° C.; yield=740 mg. Recrystallization from amethanol-chloroform solvent mixture yieldedD-6-n-propyl-8β-methoxycarbonylergoline melting at 209°-211° C.;yield=465 mg.

Analysis Calc: C, 73.05; H, 7.74; N, 8.97. Found: C, 72.84; H, 7.49; N,8.67.

EXAMPLE 6

Preparation of D-6-ethyl-8β-methylmercaptomethylergoline

A solution was prepared from 6.5 g. ofD-6-methyl-8β-hydroxymethylergoline (dihydrolysergol) and 250 ml. ofDMF. Eight grams of cyanogenbromide were added and the reaction mixturestirred at ambient temperature under a nitrogen atmosphere for about 16hours. The solvent was removed in vacuo and the residue diluted withwater and filtered. The filter cake was washed well with ethanol andether. D-6-Cyano-8β-hydroxymethylergoline thus prepared melted above260° C.

4.3 Grams of D-6-cyano-8β-hydroxymethylergoline were added to 100 ml. of6 N aqueous hydrochloric acid and the resulting acidic reaction mixturerefluxed under a nitrogen atmosphere for about 2 hours. Thin-layerchromatography of the acidic mixture indicated no mobile spots. Thereaction mixture was poured over ice and then made basic with 14 Naqueous ammonium hydroxide. The filter cake, comprising the secondaryamine D-8β-hydroxymethylergoline formed in the above reaction weighed3.65 g. and was used without further purification.

A solution of 3.65 g. of D-8β-hydroxymethylergoline in 100 ml. of DMFwas prepared to which were added 4.1 g. of potassium carbonate. 1.4 g.of ethyl iodide were added and the reaction mixture stirred at ambienttemperature under nitrogen for about 23 hours, after which time waterwas added. The aqueous mixture was extracted with several portions ofethyl acetate, the ethyl acetate extracts were combined and the combinedextracts washed with water and with saturated aqueous sodium chlorideand were then dried. Evaporation of the solvent yielded as a residueD-6-ethyl-8β-hydroxymethylergoline formed in the above reaction. Theresidue was recrystallized from a mixture of chloroform and methanol togive D-6-ethyl-8β-hydroxymethylergoline as single spot material onthin-layer chromatography; weight=1.06 g.

Analysis Calc: C, 75.52; H, 8.20; N, 10.36. Found: C, 75.60; H, 7.93; N,10.06.

A solution was prepared from 2.7 g. ofD-6-ethyl-8β-hydroxymethylergoline and 100 ml. of pyridine. 1.5 ml. ofmesyl chloride were added and the consequent reaction mixture stirredfor one hour. The reaction mixture was then diluted with water and madebasic by the addition of 14 N aqueous ammonium hydroxide. The alkalinelayer was extracted several times with ethyl acetate and the ethylacetate extracts combined. The combined extracts were washed with water,with saturated aqueous sodium chloride and then dried. Evaporation ofthe solvent yielded a residue comprisingD-6-ethyl-8β-mesyloxymethylergoline formed in the above reaction. Theresidue showed one major spot on thin-layer chromatography. The residuewas chromatographed over 200 g. of florisil using chloroform containingincreasing amounts (0 to 5%) of methanol. The chromatogram was followedby thin-layer chromatography. Fractions shown to containD-6-ethyl-8β-mesyloxymethylergoline by TLC were combined to yield 1.50g. of crystalline material melting at 184°-5° C. with decompositionafter recrystallization.

Analysis Calc: C, 62.04; H, 6.94; N, 8.04; S, 9.20. Found: C, 62.16; H,6.73; N, 8.01; S, 9.24.

A solution of 2.9 g. of methylmercaptan in 75 ml. of DMF was cooled inan ice-water mixture. 2.4 g. of sodium hydride as a 50% suspension inmineral oil was added thereto in portions, thus forming the sodium saltof methylmercaptan. The reaction mixture was allowed to warm to roomtemperature. A solution of 1.8 g. of D-6-ethyl-8β-mesyloxymethylergolinein 25 ml. of DMF was added thereto in dropwise fashion. The subsequentreaction mixture was stirred at room temperature under nitrogen for 1.25hours and was then diluted with water. The aqueous mixture was extractedwith ethyl acetate. The ethyl acetate extract was washed with water andwith saturated aqueous sodium chloride and was then dried. Evaporationof the solvent yielded a residue comprisingD-6-ethyl-8β-methylmercaptomethylergoline formed in the above reaction.The residue was substantially one spot material by thin-layerchromatography. The residue was recrystallized from a mixture of etherand hexane to yield crystallineD-6-ethyl-8β-methylmercaptomethylergoline melting at 201°-2° C. withdecomposition.

The D-6-ethyl-8β-methylmercaptomethylergoline formed in the abovereaction was suspended in 30 ml. of methanol. The suspension was heatedon a steam bath and 0.33 ml. of methanesulfonic acid were added, thusforming the methanesulfonate salt. The reaction mixture was cooled toroom temperature and then diluted with about 50 ml. of ether.D-6-Methyl-8β-methylmercaptomethylergoline methanesulfonate precipitatedupon cooling and was collected by filtration; melting point=254°-6° C.with decomposition; yield=1.80 g.

EXAMPLE 7 Preparation of D-6-n-Propyl-8-methylmercaptomethyl-8-ergolene

Eleven grams of elymoclavine were suspended in 200 ml. of DMF. About 11g. of cyanogen bromide were added and the resulting mixture stirred atroom temperature under nitrogen atmosphere for about 16 hours and wasthen diluted with water. D-6-cyano-8-hydroxymethyl-8-ergolene formed inthe above reaction precipitated and was collected by filtration;weight=8.2 g.; m.p.=215°-22° C. with decomposition. The filter cake,without further purification, was mixed with 300 ml. of acetic acid, 60ml. of water and 41 g. of zinc dust. The resulting mixture was refluxedunder a nitrogen atmosphere for about 20 hours. The reaction mixture wasthen filtered and the filtrate poured over ice. The filtrate was thenmade strongly basic with 14 N aqueous ammonium hydroxide. The alkalinelayer was extracted several times with a mixture of chloroform andisopropanol. The extracts were combined and the combined extracts washedwith saturated aqueous sodium chloride and then dried. Removal of thesolvent left a residue consisting of D-8-hydroxymethyl-8-ergolene andits acetate ester. Without further purification, the residue wasdissolved in 200 ml. of DMF to which was added 6.2 g. of potassiumcarbonate and 8 ml. of n-propyl iodide. This reaction mixture wasstirred under nitrogen for about 6 hours and was then diluted withwater. The aqueous layer was extracted several times with ethyl acetateand the ethyl acetate extracts combined and washed with water and withsaturated aqueous sodium chloride and then dried. Evaporation of thesolvent yielded a residue which was seen to have two major spots bythin-layer chromatography. The residue was dissolved in 100 ml. ofmethanol and 100 ml. of dioxane. 25 ml. of 2 N aqueous sodium hydroxidewere added and the alkaline mixture stirred under nitrogen for 1.25hours at room temperature. The reaction mixture was then diluted withwater and the aqueous layer extracted several times with achloroform-isopropanol solvent mixture. The organic extracts werecombined and the combined extracts washed with saturated aqueous sodiumchloride and then dried. Evaporation of the solvent yielded as residuecomprising one major spot by TLC. The residue was dissolved inchloroform and the chloroform solution chromatographed over 200 g. offlorisil. Chloroform containing increasing amounts (2-5%) methanol wasused as the eluant. Fractions shown by TLC to containD-6-propyl-8-hydroxymethyl-8-ergolene were combined. The solvent wasevaporated to dryness and the resulting residue crystallized from etherto yield D-6-n-propyl-8-hydroxymethyl-8-ergolene melting at 189°-191° C.with decomposition; weight=2.9 g.

Analysis Calc: C, 76.56; H, 7.85; N, 9.92. Found: C, 76.30; H, 7.85; N,9.96.

Eight and one-tenth grams of D-6-n-propyl-8-hydroxymethyl-8-ergolenewere suspended in 1000 ml. of acetonitrile containing 39.3 g. oftriphenylphosphine and 14.4 ml. of carbon tetrachloride--for thisreagent see Tetrahedron, 23, 2789 (1967). The consequent reactionmixture was stirred at room temperature under a nitrogen atmosphere for19 hours. Volatile constituents were then removed in vacuo and theresidue diluted with aqueous tartaric acid. The acidic aqueous layer wasextracted several times with toluene and the toluene extracts discarded.The aqueous layer then made basic with sodium bicarbonate and thealkaline layer extracted several times with a mixture of chloroform andisopropanol. The organic extracts were separated, and the separatedextracts washed with saturated aqueous sodium chloride and then dried.Evaporation of the solvent yielded a residue which showed one major spoton TLC. A solution of the residue in a mixture of chloroform andmethanol (2%) was chromatographed over 200 g. of florisil. Fractionsshown to contain D-6-n-propyl-8-chloromethyl-8-ergolene formed in theabove reaction as shown by TLC were combined and the solvent removedtherefrom in vacuo. Recrystallization of the resulting residue from amixture of chloroform and methanol yieldedD-6-n-propyl-8-chloromethyl-8-ergolene which decomposed at about 185°C.; weight=4.65 g.; second fraction=2.30 g.

Analysis Calc: C, 71.87; H, 7.04; N, 9.31. Found: C, 71.62; H, 6.89; N,9.57.

Fifty milliliters of a solution of 25 g. of methylmercaptan in 100 ml.of DMA was diluted with 200 ml. of DMA and the resulting solution cooledin an ice-water mixture. 10.6 g. of sodium hydride as a 50% suspensionin mineral oil were added thereto in portions. The reaction mixture wasallowed to warm to 75° C. at which point a solution of 6.7 g. ofD-6-n-propyl-8-chloromethyl-8-ergolene in 75 ml. of DMA was addedrapidly in dropwise fashion. The reaction mixture was stirred for 2hours at room temperature under nitrogen. The reaction mixture was thencooled, diluted with water, and the aqueous mixture extracted with ethylacetate. The ethyl acetate solution was separated, washed with water andwith saturated aqueous sodium chloride and then dried. Evaporation ofthe organic solvent left a residue which was substantially one spotmaterial by TLC. A chloroform solution of the residue waschromatographed over 200 g. of florisil using chloroform containingincreasing amounts (0 to 3%) of methanol as the eluant. Fractions shownto contain D-6-n-propyl-8-methylmercaptomethyl-8-ergolene by TLC werecombined and the organic solvent removed from the combined extracts.Recrystallization of the residue first from ether and then from ethanolyielded 2.70 g. of D-6-n-propyl-8-methylmercaptomethyl-8-ergolenemelting at 180°-3° C. with decomposition. Treatment of the residue withmaleic acid yielded the maleate salt ofD-6-n-propyl-8-methylmercaptomethyl-8-ergolene as an amorphous solid.

Analysis Calc: C, 64.46; H, 6.59; N, 6.54; S, 7.48. Found: C, 64.31; H,6.51; N, 6.81; S, 7.61.

EXAMPLE 8 Preparation of D-6-n-propyl-8β-methylmercaptomethyl-9-ergolene

Twenty-five grams of methyl lysergate were dissolved in 750 ml. ofmethylenedichloride. 35 g. of cyanogenbromide were added and theresulting mixture stirred at room temperature under nitrogen for 22hours. The organic layer was washed with aqueous tartaric acid, waterand saturated aqueous sodium chloride. The organic layer was then driedand the organic solvent removed therefrom by evaporation. The resultingresidue containing D-6-cyano-8β-methoxycarbonyl-9-ergolene formed in theabove reaction showed a single major spot on TLC. The residue wasdissolved in 600 ml. of acetic acid and 120 ml. of water to which wasadded 80 g. of zinc dust. The resulting mixture was heated to refluxtemperature under nitrogen for 181/2 hours. The reaction mixture wasthen cooled and filtered. The filtrate was poured over ice and then madebasic with 14 N aqueous ammonium hydroxide. The alkaline mixture wasextracted several times with chloroform. The chloroform extracts werecombined, the combined extracts washed with saturated aqueous sodiumchloride and then dried. The product of this reactionmethyl-D-6-desmethyllysergate contained some of the correspondingisolysergate. The residue, without further purification, was dissolvedin DMF and alkylated with n-propyl iodide and potassium carbonate by theprocedure of Example 7 to yieldD-6-n-propyl-8β-methoxycarbonyl-9-ergolene containing a small amount ofthe α-methoxycarbonyl isomer. The residue was suspended in ether and thesuspension chromatographed over 150 g. of florisil using ether as theeluant. Those fractions shown to consist mainly of the β-isomer by NMRwere combined and the ether removed therefrom by evaporation. Theresulting residue was dissolved in ethyl acetate and the organic layerextracted with aqueous tartaric acid. The aqueous extract was separatedand then made basic with 14 N aqueous ammonium hydroxide. The nowalkaline layer was extracted several times with chloroform, thechloroform extracts were combined, and the combined extracts washed withsaturated aqueous sodium chloride and then dried. Evaporation of thechloroform yielded a residue which gave one major spot on TLC. Theresidue was rechromatographed over 30 g. of florisil using anether-hexane (1:1) solvent mixture as the eluant. Fractions shown tocontain D-6-n-propyl-8β-methoxycarbonyl-9-ergolene by TLC and NMR werecombined and reduced with lithium aluminum hydride as follows: 0.67grams of residue were dissolved in 75 ml. of THF to which was added inportions 0.5 g. of lithium aluminum hydride. The reaction mixture wasstirred at room temperature for 70 minutes and then cooled in anice-water bath. The organometallics and excess hydride were decomposedby the seriatim addition of ethyl acetate and 10% aqueous sodiumhydroxide. The reaction mixture was filtered and the filtrate dilutedwith water. The aqueous mixture was extracted several times with achloroform-isopropanol solvent mixture. The organic extracts werecombined and the combined extracts washed with saturated aqueous sodiumchloride and then dried. Evaporation of the solvent yielded a residuewhich was shown by TLC to contain three major spots. A chloroformsolution of the residue was chromatographed over 30 g. of florisil usingchloroform containing increasing amounts (2-10%) of methanol. Fourfractions were obtained, each of which was treated separately with 10ml. of pyridine containing 0.5 ml. of methanesulfonylchloride. Eachreaction mixture was diluted with water and then made basic withconcentrated ammonium hydroxide. The alkaline solution was in eachinstance extracted with ethyl acetate and the ethyl acetate extractwashed with saturated aqueous sodium chloride and then dried. The fourthof the chromatographic fractions so treated was shown by NMR to consistof D-6-n-propyl- 8β-mesyloxymethyl-9-ergolene. The compound wasrefiltered through florisil to yield 250 mg. of material melting atabout 150° C. with decomposition. Next, 1.40 ml. of a solutioncontaining 25 g. of methylmercaptan in 100 ml. of DMA was added to 40ml. of DMA and the mixture cooled in an ice-water bath. 240 mg. ofsodium hydride as a 50% suspension in mineral oil was next added inportions to the cooled solution. The consequent reaction mixture waswarmed to about 15° C. A solution of 250 mg. ofD-6-n-propyl-8β-mesyloxymethyl-9-ergolene in 10 ml. of DMA was addedrapidly in dropwise fashion. The resulting reaction mixture was stirredat room temperature under nitrogen atmosphere for 1.25 hours after whichtime it was cooled and diluted with water. The resulting aqueous mixturewas extracted several times with ethyl acetate. The ethyl acetate layerswere separated and combined and the combined layers washed with waterand with saturated aqueous sodium chloride. The combined organic layerwas dried and the organic solvent was removed by evaporation. Theresidue was seen to be essentially one spot material on TLC. A solutionof the residue in ether was filtered through florisil and the florisilwashed with ether. The ether solution was then diluted with hexane toyield crystalline D-6-n-propyl-8β-methylmercaptomethyl-9-ergolene formedin the above reaction. The compound decomposed at about 197° C.;yield=100 mg.

Analysis Calc.: C, 73.03; H, 7.74; N, 8.97; S, 10.26. Found: C, 73.05;H, 7.94; N, 9.26; S, 10.31.

EXAMPLE 9 Preparation ofD-2-bromo-6-n-propyl-8β-methylmercaptomethylergoline

A solution of 1.62 g. of N-bromosuccinimide in 50 ml. of dioxane wasadded rapidly in dropwise fashion to a solution of 2.60 g. ofD-6-n-propyl-8β-methoxycarbonylergoline in 100 ml. of dioxane at about63° C. The reaction mixture was heated for two hours in the range60°-65° C. under a nitrogen atmosphere. The reaction mixture was thenpoured over ice and 14 N aqueous ammonium hydroxide. The alkalinemixture was extracted with ethyl acetate and the ethyl acetate extractseparated and washed with water and then with saturated aqueous sodiumchloride. The ethyl acetate layer was dried and the solvent removed byevaporation. Thin-layer chromatography of the residue showed one majorspot. A chloroform solution of the residue containingD-2-bromo-6-n-propyl-8β-methoxycarbonylergoline formed in the abovereaction was chromatographed over 35 g. of florisil using chloroformcontaining 1 percent methanol as the eluant. Fractions shown to containthe major spot material by TLC were combined to yield 1.64 g. ofD-2-bromo-6-n propyl-8β-methoxycarbonylergoline melting at 167°-8° C.Recrystallization from methanol yielded material melting at 168°-9° C.

Analysis Calc.: C, 58.32; H, 5.92; N, 7.16. Found: C, 58.46; H, 5.76; N,7.20.

A solution of 1.4 g. of D-2-bromo-6-n-propyl-8β-methoxycarbonylergolinein 100 ml. of THF was cooled in an ice-water mixture. 1.5 g. of lithiumaluminum hydride were added in portions. The reaction mixture wasstirred at room temperature for about an hour and then cooled. Theexcess lithium aluminum hydride and any organometallic substancespresent were decomposed by the seriatim addition of ethyl acetate and 10percent aqueous sodium hydroxide. The reaction mixture was furtherdiluted with water, and the aqueous layer extracted with a mixture ofchloroform and isopropanol. The organic extract was separated, washedwith saturated aqueous sodium chloride, and dried. Evaporation of thechloroform yielded a residue which gave 1 major spot on TLC.Recrystallization of the residue from methanol yieldedD-2-bromo-6-n-propyl-8β-hydroxymethylergoline formed in the abovereaction; melting point=208°-210° C.; yield=1.19 g.

Analysis Calc.: C, 59.51; H, 6.38; N, 7.71; Br, 21.99. Found: C, 59.55;H, 6.14; N, 7.50; Br, 21.72.

A solution of 1.3 g. of D-2-bromo-6-n-propyl-8β-hydroxymethylergolinewas prepared in 50 ml. of pyridine. 1.5 ml. of methanesulfonylchloridewere added and the subsequent reaction mixture stirred for 1.5 hours.The reaction mixture was then poured over a mixture of ice and 14 Naqueous ammonium hydroxide. The alkaline aqueous layer was extractedwith ethyl acetate and the ethyl acetate layer separated and washed withwater and with saturated aqueous sodium chloride. The ethyl acetatesolution was dried and the ethyl acetate removed by evaporation. Theresidue was shown by thin layer chromatography to consist of one majorspot. Recrystallization of the residue from methanol yieldedD-2-bromo-6-n-propyl-8β-mesyloxymethylergoline; yield=1.43 g.

Analysis Calc.: C, 50.74; H, 6.17; N, 5.92. Found: C, 50.90; H, 6.03; N,6.00.

Eight milliliters of a solution of methylmercaptan in DMA (40 millimolesof methylmercaptan) and 100 ml. of DMA were cooled in an ice-water bath.1.6 g. of sodium hydride as a 50 percent suspension in mineral oil wasadded thereto in portions. The mixture was allowed to warm to about 15°C. at which point a solution of 1.5 g. ofD-2-bromo-6-n-propyl-8β-mesyloxymethylergoline in 40 ml. of DMA wasadded thereto rapidly in dropwise fashion. The consequent reactionmixture was stirred at room temperature under nitrogen for 1.5 hoursafter which time it was cooled and diluted with water. The aqueous layerwas extracted several times with ethyl acetate and the ethyl acetateextracts separated and combined. The combined extracts were washed withwater and with saturated aqueous sodium chloride and then dried.Evaporation of the solvent in vacuo yielded a residue consisting of 1major spot. Recrystallization of the residue from methanol yieldedD-2-bromo-6-n-propyl-8β-methylmercaptomethylergoline formed in the abovereaction melting at 159°-161° C. (Total yield=1.08 g.).

The methanesulfonate salt was prepared by dissolving 950 mg. ofD-2-bromo-6-n-propyl-8β-methylmercaptomethylergoline in about 25 ml. ofhot methanol. 0.16 ml. of a methanesulfonic acid solution containing 2.5millimoles of acid were added and the solution chilled. The reactionmixture was then diluted with ether and 940 mg. of the methanesulfonatesalt melting at 256° C. with decomposition were obtained.

The starting material for the above reaction,D-6-n-propyl-8β-methoxycarbonylergoline can be prepared from methyldihydrolysergate by the same sequence of reactions as employed inExample 8 to prepare the corresponding 6-n-propyl derivative of methyllysergate itself.

EXAMPLE 10 Preparation of D-6-n-propyl-8β-methylsulfinylmethylergoline.

A solution was prepared by dissolving 1.2 g. of the methanesulfonatesalt of D-6-n-propyl-8β-methylmercaptomethylergoline in 100 ml. ofwater. A solution containing 685 mg. of sodium periodate in 25 ml. ofwater was added thereto and the resulting reaction mixture stirred atroom temperature for 17 hours. The reaction mixture was then dilutedwith aqueous sodium bicarbonate and the alkaline layer extracted with amixture of chloroform and isopropanol. The organic extract wasseparated, washed with saturated aqueous sodium chloride and dried.Evaporation of the solvent yielded a residue which was dissolved inboiling methanol to which 0.2 ml. of methanesulfonic acid had beenadded. The solution was cooled to room temperature and diluted with anequal volume of ether. The solvents were removed in vacuo and theresidue dissolved in 100 ml. of boiling acetone. The acetone solutionwas filtered and cooled. The crystalline methanesulfonate salt ofD-6-n-propyl-8β-methylsulfinylmethylergoline melting at 200°-9° C. withdecomposition was obtained.

Analysis Calc: C, 56.31; H, 7.09; N, 6.57; S, 15.03. Found: C, 56.09; H,6.85; N, 6.41; S, 14.86.

The corresponding free base was prepared by standard procedures andmelted at 173°-5° C. with decomposition.

Analysis Calc.: C, 69.05; H, 7.93; N, 8.48; S, 9.70. Found: C, 68.99; H,7.68; N, 8.71; S, 9.76.

EXAMPLE 11 Preparation of D-6-propyl-8β-methylsulfonylmethylergoline

A reaction mixture was prepared from 3.6 g. ofD-6-propyl-8β-mesyloxymethylergoline, 10 g. of sodium methanesulfinateand 200 ml. of DMF. The mixture was heated at 110° C. under nitrogen for3.75 hours. The reaction mixture was then diluted with water and theaqueous mixture extracted several times with ethyl acetate. The ethylacetate layers were combined and the combined layers washed with water,with saturated aqueous sodium chloride and were then dried. Evaporationof the ethyl acetate yielded a residue comprisingD-6-n-propyl-8β-methylsulfonylmethylergoline formed in the abovereaction. The residue was dissolved in chloroform and the chloroformsolution chromatographed over 200 g. of fluorosil using chloroformcontaining increasing amounts (2-4 percent) of methanol as eluant. Twomajor fractions were obtained, one moving just ahead of startingmaterial on thin-layer chromatography and one moving just behind.Fractions containing this second slower moving component, were combinedand the solvent evaporated therefrom. Recrystallization of the residuefrom methanol yielded crystallineD-6-n-propyl-8β-methylsulfonylmethylergoline melting at 184°-6° C.(total yield =690 mg.).

Analysis Calc.: C, 65.86; H, 7.56; N, 8.09; S, 9.25. Found: C, 66.08; H,7.49; N, 7.88; S, 9.05.

The methanesulfonic acid salt was prepared according to standardprocedures in methanol.

EXAMPLE 12 Preparation ofD-2-chloro-6-n-propyl-8β-methylmercaptomethylergoline

7.2 Grams of D-6-n-propyl-8β-mesyloxymethylergoline were dissolved in100 ml. of methylene dichloride and 380 ml. of acetonitrile. 6.3 ml. ofborontrifluoride etherate were added and the mixture cooled in the range0°-5° C. Next, over a 10-minute period, a solution of 1.80 ml. ofsulfuryl chloride in 20 ml. of methylene dichloride was added indropwise fashion. The reaction mixture was stirred with cooling forabout 30 minutes and then diluted with 5% aqueous ammonium hydroxide.The alkaline layer was extracted several times with a mixture ofchloroform and isopropanol. The organic extracts were combined and thecombined extracts washed with saturated aqueous sodium chloride and thendried. The solvent was removed by evaporation and the resulting residuedissolved in methylene dichloride. The methylene dichloride solution waschromatographed over 200 g. of florosil using methylene dichloridecontaining increasing amounts (2-3 percent) of methanol as the eluant.The chromatogram was followed by thin-layer chromatography. Fractionscontaining a material moving slightly faster than starting material werecollected and the solvent evaporated therefrom in vacuo. This fractioncontaining D-2-chloro-6-n-propyl-8-mesyloxymethylergoline formed in theabove reaction was recrystallized from methanol to yield crystallinematerial melting at 130°-1° C. (82 percent yield). A secondrecrystallization from methanol yielded compound melting at 133°-5° C.

Analysis Calc.: C, 57.49; H, 6.35; N, 7.06; Cl, 8.93; S, 8.08 Found: C,57.29; H, 6.20; N, 7.12; Cl, 9.13; S, 8.21.

A solution of 7 g. of methylmercaptan in 200 ml. of DMF was cooled in anice-water bath to about 0° C. 9.6 g. of sodium hydride as a 50 percentsuspension in mineral oil was added thereto in portions, thus formingmethyl mercaptide. The cooling bath was removed and stirring continuedfor about 10 minutes at which time, a solution of 6.2 g. ofD-2-chloro-6-n-propyl-8β-mesyloxymethylergoline in 75 ml. of DMF wasadded rapidly in dropwise fashion. The reaction mixture was stirred foran additional hour under nitrogen and then diluted with water. Theaqueous solution was extracted several times with ethyl acetate. Theethyl acetate extracts were combined and then combined layers washedwith water and then with saturated aqueous sodium chloride. The ethylacetate layer was dried and the ethyl acetate removed therefrom byevaporation. The residue was washed with ether and the ether washdiluted with hexane. 4.40 g. of crystalline material melting at 183°-6°C. comprising D-2-chloro-6-n-propyl-8β -methylmercaptomethylergolineformed in the above reaction were obtained. The compound was convertedto the methane sulfonate salt which melted at 267°-9° C. withdecomposition after recrystallization from a methanol-ether solvent.

Analysis Calc.: C, 53.98; H, 6.57; N, 6.29; Cl, 7.97; S, 14.41. Found :C, 54.22; H, 6.64; N, 6.45; Cl, 8.13; S, 14.20.

As evidence of the utility of the compounds of this invention in thetreatment of Parkinson's Syndrome, it has been found that they affectturning behavior in a test procedure utilizing6-hydroxydopamine-lesioned rats. In this test,nigro-neostriatal-lesioned rats are employed, which are prepared by theprocedure of Ungerstedt and Arbuthnott, Brain Res, 24, 485 (1970). Acompound having dopamine agonist activity causes the rats to turn incircles contralateral to the side of the lesion. After a latency period,which varies from compound to compound, the number of turns is countedover a 15-minute period. D-6-n-propyl-8β-methylmercaptomethylergolinemesylate not only had a very short latency period of 6 or 7 minutes butproduced an average of 105 turns per lesioned rat.

Results obtained from testing this compound and other related compoundsin the rat turning test are set forth in Table 1 below. The compoundswere dissolved in water and the aqueous solution injected into the ratby the intraperitoneal route. In the table, column 1 gives the name ofthe compound, column 2, the IP dose in mg./kg., column 3, percent oftest animals exhibiting turning behavior, column 4, latency of effect,column 5, duration of effect, and column 6, average number of turnsobserved in first 15 minutes after end of latency period.

                                      Table I                                     __________________________________________________________________________                          % of Rats                                                                IP   Exhibiting                                                                          Latency of                                                                          Duration                                                                           Average                                                 Dose in                                                                            Turning                                                                             Effect in                                                                           of Effect                                                                          Number of                              Name of Compound mg./kg.                                                                            Behavior                                                                            Minutes                                                                             in Hours                                                                           Turns/rat                              __________________________________________________________________________    D-6-n-propyl-8β-methylmercapto-                                          methylergoline mesylate                                                                        1    100   5-7   24+  105                                    D-6-ethyl-8β-methylmercapto-                                             methylergoline mesylate                                                                        1    100   9     2+   112                                    D-6-n-propyl-8β-methylmercapto-                                          methyl-9-ergolene                                                                              1    100   4     2+   200                                    D-6-n-propyl-8-methylmercapto-                                                methyl-8-ergolene maleate                                                                      1    100   4     1    118                                    D-2-bromo-6-n-propyl-8β-methyl-                                          mercaptomethylergoline mesylate                                                                1    100   5     1     71                                    D-6-n-propyl-8β-methylsulfinyl                                           methylergoline mesylate                                                                        1    100   7     1     65                                    D-6-methyl-8β-methylmercapto-                                            methylergoline mesylate*                                                                       1     50   30-45 ˜2                                                                            51                                    D-6-n-propyl-8β-methoxymethyl-                                           ergoline mesylate                                                                              1    100   6     2+   111                                    __________________________________________________________________________     *from U.S. Pat. No. 3,901,894                                            

The compounds of this invention are also useful as prolactin inhibitorsand as such they can be employed in the treatment of inappropriatelactation such as postpartum lactation and galactorrhea. Furthermore thecompounds are useful in the treatment of Parkinson's syndrome.

As evidence of their utility in the treatment of diseases in which it isdesirable to reduce the prolactin level, the compounds of this inventionhave been shown to inhibit prolactin according to the followingprocedure.

Adult male rates of the Sprague-Dawley strain weighing about 200 g. werehoused in an air-conditioned room with controlled lighting (lights on 6a.m.-8 p.m.) and fed lab chow and water ad libitum. Each rat received anintraperitoneal injection of 2.0 mg. of reserpine in aqueous suspension18 hours before administration of the ergoline derivative. The purposeof the reserpine was to keep prolactin levels uniformly elevated. Thecompounds under test were dissolved in 10 percent ethanol at aconcentration of 10 mcg.ml. and were injected intraperitoneally at astandard dose of 50 mcg/kg. Each compound was administered to a group of10 rats, and a control group of 10 intact males received an equivalentamount of 10 percent ethanol. One hour after treatment all rats werekilled by decapitation, and 150 μl aliquots of serum were assayed forprolactin. The results were evaluated statistically using Student's "t"test to calculate the level of significance, "p", of the changes inprolactin level.

The difference between the prolactin level of the treated rats andprolactin level of the control rats, divided by the prolactin level ofthe control rats gives the percent inhibition of prolactin secretionattributable to the compounds of this invention. These inhibitionpercentages are given in Table 2 below. In the table, column 1 gives thename of the compound; column 2, the prolactin level for each group ofrats; column 3, the percent prolactin inhibition; and column 4, thelevel of significance. The data were collected from three separateexperiments, each with its own control, and Table 2 sets forth theresults obtained by experiment.

                                      Table II                                    __________________________________________________________________________                              Percent                                                              Serum Prolactin                                                                        Inhibition of                                                                          Significance                               Name of Compound Level (mg/ml)                                                                          Serum Prolactin                                                                        Level "P"                                  __________________________________________________________________________    Experiment 1                                                                  Control          30.4 ± 3.4                                                                          --       --                                         D-6-n-propyl-8β-methylmercapto-                                          methylergoline mesylate                                                                        1.6 ± 0.4                                                                           95%      <0.001                                     D-6-methyl-8β-methylmercapto-                                            methylergoline mesylate*                                                                       12.8 ±                                                                              58%      <0.01                                      Experiment 2                                                                  Control          55.2 ± 4.1                                                                          --       --                                         D-6-n-propyl-8β-methoxymethyl-                                           ergoline mesylate                                                                              2.4 ± 0.2                                                                           96%      <0.001                                     Experiment 3                                                                  Control          42.3 ± 7.3                                                                          --       --                                         D-6-ethyl-8β-methylmercapto-                                             methylergoline mesylate                                                                        3.9 ± 0.4                                                                           91%      <0.001                                     D-6-n-propyl-8β-methylmercapto-                                          methyl-9-ergolene                                                                              8.1 ± 1.2                                                                           81%      <0.001                                     D-6-n-propyl-8-methylmercapto-                                                methyl-8-ergolene maleate                                                                      3.9 ± 0.2                                                                           91%      <0.001                                     Control          42.3 ± 7.3                                                                          --       --                                         D-6-ethyl-8β-methylmercapto-                                             methylergoline mesylate                                                                        3.9 ± 0.4                                                                           91%      <0.001                                     D-6-n-propyl-8β-methylmercapto-                                          methyl-9-ergolene                                                                              8.1 ± 1.2                                                                           81%      <0.001                                     D-6-n-propyl-8-methylmercapto-                                                methyl-8-ergolene maleate                                                                      3.9 ± 0.2                                                                           91%      <0.001                                     D-2-bromo-6-n-propyl-8β-methyl-                                          mercaptomethylergoline mesylate                                                                4.6 ± 0.4                                                                           89%      <0.001                                     D-6-n-propyl-8β-methylsulfinyl-                                          methylergoline mesylate                                                                        3.3 ± 92%1     <0.001                                     __________________________________________________________________________     *from U.S. Pat. No. 3,901,894.                                           

Employing dose response curves, it has been determined thatD-6-n-propyl-8β-methylmercaptomethylergoline mesylate is about 100 timesmore potent as a prolactin inhibitor than is the correspondingD-6-methyl compound and about 30 times more potent in the turningbehavior test in 6-hydroxydopamine-lesioned rats than the correspondingD-6-methyl derivative.

In addition, compounds of this invention, particularlyD-6-n-propyl-8β-methylmercaptomethylergoline and its Δ⁸ and Δ⁹congeners, are extremely potent inhibitors of the high affinity bindingof tritiated dopamine to dopamine receptors present in membranes fromstriatal synaptosomes of bovine brain--see Bymaster and Wong, Fed.Proc., 36, 1006 (1977) and thus likely to be useful in the treatment ofParkinsonism. Table 3 which follows gives a series of determinations ofthe inhibiting power of several ergolines, 8-ergolenes and 9-ergolenes,both from this invention and from the prior art. In the table, column 1gives the name of the compound and column 2, K_(i) (in nanomoles), theconcentration of inhibitor required to slow the reaction of one-half ofthe initial reaction rate.

                  Table 3                                                         ______________________________________                                                                 K.sub.1 (nM)                                         ______________________________________                                        Name of Compound                                                              D-6-n-propyl-8β-methylmercapto-                                          methylergoline mesylate  3 ± 1                                             D-6-n-propyl-8-methylmercapto-                                                methyl-8-ergolene maleate                                                                              2                                                    D-6-n-propyl-8β-methylmercapto-                                          methyl-9-ergolene        2                                                    D-2-bromo-6-n-propyl-8β-methyl-                                          mercaptomethylergoline mesylate                                                                        3                                                    D-6-allyl-8β-methylmercapto-                                             methylergoline mesylate  5                                                    D-6-ethyl-8β-methylmercapto-                                             methylergoline mesylate  3.5                                                  D-6-n-propyl-8β-methoxymethyl-                                           ergoline mesylate        10                                                   Prior Art Compounds                                                           D-6-methyl-8β-methylmercapto-                                            methylergoline mesylate  13                                                   D-6-methyl-8β-methoxymethyl-                                             ergoline mesylate        75                                                   D-6-methyl-8β-methylmercapto-                                            methyl-9-ergolene        6                                                    D-2-chloro-6-methyl-8β-methyl-                                           mercaptomethylergoline mesylate                                                                        6                                                    ______________________________________                                    

The compounds of this invention, particularlyD-6-n-propyl-8β-methylmercaptomethylergoline are, surprisingly,serotonin agonists rather than serotonin antagonists as are mostergolenes or ergolines.

In using the compounds of this invention to inhibit prolactin secretionor to treat Parkinson's syndrome or for other pharmacologic action, anergoline, 8-ergolene or 9-ergolene according to Formula II above, or asalt thereof with a pharmaceutically-acceptable acid, is administered toa subject from Parkinsonism or in need of having their prolactin levelreduced in amounts ranging from 0.01 to 3 mg per kg. of mammalianweight. For D-6-n-propyl-8δ-methylmercaptomethylergoline, a dose rangeof 0.01 to 0.5 is used. Oral administration is preferred. If parenteraladministration is used, the injection is preferably by the subcutaneousroute using an appropriate pharmaceutical formulation. Other modes ofparenteral administration such as intraperitoneal, intramuscular, orintravenous routes are equally effective. In particular, withintravenous or intramuscular administration, a water solublepharmaceutically-acceptable salt is employed. For oral administration, acompound according to Formula II either as the free base or in the formof a salt thereof can also be mixed with standard pharmaceuticalexcipients and loaded into empty telescoping gelatin capsules or pressedinto tablets.

We claim:
 1. A process for inhibiting the secretion of prolactin inmammals which comprises administering to a mammal in which there is anexcess of prolactin being secreted a prolactin-lowering dose of acompound of the formula ##STR3## wherein Y is O, SO, SO₂ or S, R¹ isethyl, n-propyl, or allyl, X is H, Cl or Br and R², R³ and R⁴ when takensingly are hydrogen, and R² and R³, and R³ and R⁴, when taken togetherwith the carbon atoms to which they are attached, form a double bond,and pharmaceutically-acceptable acid addition salts thereof.
 2. Aprocess for treating a patient suffering from Parkinson's syndrome andin need of treatment which comprises administering a dose effective toameliorate the Parkinsonism symptoms of a compound of the formula##STR4## wherein Y is O, SO, SO₂ or S, R¹ is ethyl, n-propyl, or allyl,X is H, Cl or Br and R², R³ and R⁴ when taken singly are hydrogen, andR² and R³, and R³ and R⁴, when taken together with the carbon atoms towhich they are attached, form a double bond, andpharmaceutically-acceptable acid addition salts thereof.
 3. A methodaccording to claim 2 in whichD-6-n-propyl-8β-methylmercaptomethylergoline or a pharmaceuticallyacceptable salt thereof is administered.